Compare

Elekta AB/Skr EKTA B

1D1W1M3M6MYTD1Y5YMAX

About Elekta AB

Elekta AB is a Swedish company specializing in the development and production of medical technologies used in radiotherapy and radiosurgery for treating cancer and brain disorders. Founded in 1972 and headquartered in Stockholm, Sweden, Elekta offers a range of products including linear accelerators, brachytherapy solutions, and software for treatment planning and digital health records management. The company is recognized for its emphasis on precision and efficiency in treatment delivery. Elekta operates globally, serving hospitals and cancer care centers across multiple continents, leveraging technological innovations to improve patient outcomes and workflow efficiency in healthcare facilities. Its strategic focus includes the continuous advancement of image-guided radiation therapy technologies.
Ticker
Skr EKTA B
Sector
Health
Primary listing
XSTO
Employees
3,996
Headquarters
Stockholm, Sweden
Website
www.elekta.com

Elekta AB Metrics

BasicAdvanced
kr 23B
-
-kr 0.95
0.97
kr 2.40
4.09%

What the Analysts think about Elekta AB

Analyst ratings (Buy, Hold, Sell) for Elekta AB stock.
Analyst projections of the future price of Elekta AB stock.

Bulls say / Bears say

Order intake rose for a third consecutive quarter, and the Q1 book-to-bill ratio reached 1.11, supported by demand for Elekta Evo and Elekta ONE. This gives the sales recovery a firmer backlog base, though conversion still matters. (Elekta)
Profitability is recovering: Q1 adjusted EBIT margin rose to 11.2% from 6.5%, while the restructuring programme is delivering more than SEK 500 million in annualised savings. Continued pricing discipline and cost control could support the full-year margin target. (Elekta, Elekta)
Elekta is extending adaptive radiotherapy across more treatment systems, while recent clinical data on its Unity platform adds evidence behind the technology. If hospitals adopt these workflows more widely, the broader portfolio could support future equipment and software demand. (Elekta, Elekta)
Sales fell 2% in constant currencies in Q1, with China and APJ weakening, and analysts said the miss reflected sluggish regional demand. Elekta is still growing more slowly than the radiotherapy market, putting pressure on its ability to turn a recovery into durable growth. (Elekta, Investing.com)
China remains a material risk: revenue there dropped 16% in Q1, while proposed volume-based procurement could make prices more transparent and intensify price pressure. Analysts also flagged installation delays and competition in the US. (MarketScreener, MarketScreener Sverige)
Q1 free cash flow before dividends and acquisitions remained negative at SEK 266 million, as inventory build-up weighed on working capital. If stock levels do not convert into deliveries and cash, the improvement in reported earnings may not translate into stronger cash generation. (Elekta)
Data summarised monthly by Lightyear AI. Last updated on 25 Oct 2026.

Elekta AB Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

Elekta AB Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

Funds containing Elekta AB

Funds
Fund name
Fund size
Skr EKTA B weighting
L&G ROBO Global Robotics and Automation$ROBO
$1.7B1.14%
L&G ROBO Global Robotics and Automation£ROBG
$1.7B1.14%
iShares Healthcare Innovation£DRDR
$1.3B0.21%
iShares Healthcare Innovation€2B78
$1.2B0.21%
iShares Healthcare Innovation$HEAL
$1.3B0.21%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.